Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial

• Main Authors: Chuanchuan Nan (Author), Xiaowu Zhang (Author), Wei Huang (Author), Biao Zhu (Author), Jianghong Zhao (Author), Song Lu (Author), Lewu Xian (Author), Kaizhong Liu (Author), Gang Ma (Author), Wei Yang (Author), Mingguang Huang (Author), Dongmin Zhou (Author), Ming Zhang (Author), Yan Duan (Author), Guixin Wu (Author), Zhengying Jiang (Author), Li Zhang (Author), Xinrong He (Author), Yuhong Chen (Author), Xuezhong Xing (Author), Changsong Wang (Author), Donghao Wang (Author), Kaijiang Yu (Author)
• Format: Book
• Published: Elsevier, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Carrimycin is a potential immune-regulating agent for sepsis in patients with tumors. In this study, we investigated its effects on inflammation and immune function in tumor patients with sepsis. In total, 120 participants were randomized to receive either carrimycin treatment (400 mg/day) (n = 62)...